Edition:
United Kingdom

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

2.33USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
138,034
52-wk High
$12.95
52-wk Low
$2.32

Latest Key Developments (Source: Significant Developments)

Newlink Genetics Says Reduced Its Workforce By 25 Employees
Tuesday, 31 Jul 2018 

July 31 (Reuters) - NewLink Genetics Corp ::NEWLINK GENETICS CORP SAYS ON JULY 26, 2018, BOARD OF COMPANY APPROVED, AND MANAGEMENT COMMENCED AND COMPLETED ON JULY 26, 2018.NEWLINK GENETICS CORP SAYS ON JULY 26, COMPLETED RESTRUCTURING PLAN TO REDUCE OPERATING COSTS AND BETTER ALIGN WORKFORCE WITH NEEDS OF ITS BUSINESS.NEWLINK GENETICS CORP SAYS UNDER PLAN, COMPANY REDUCED ITS WORKFORCE BY 25 EMPLOYEES (APPROXIMATELY 30%).NEWLINK GENETICS CORP SAYS EXPECTS THAT WORKFORCE REDUCTION WILL DECREASE COMPANY'S CASH PAYROLL EXPENSE BY APPROXIMATELY $4.8 MILLION ANNUALLY.NEWLINK GENETICS CORP SAYS ESTIMATES TO INCUR AGGREGATE RESTRUCTURING CHARGES OF ABOUT $1.4 MILLION, WHICH WILL BE RECORDED IN Q3 OF 2018.  Full Article

Newlink Genetics Reports Q2 Loss Per Share Of $0.47
Tuesday, 31 Jul 2018 

July 31 (Reuters) - NewLink Genetics Corp ::Q2 LOSS PER SHARE $0.47.SAYS HAS COMPLETED AN ORGANIZATIONAL REALIGNMENT.SAYS ORGANIZATIONAL CHANGES INCLUDE A REDUCTION IN HEADCOUNT OF APPROXIMATELY 30%.SAYS CARL LANGREN HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER.SAYS AS A RESULT OF ORGANIZATIONAL CHANGES, COMPANY ANTICIPATES ITS CURRENT CASH RUNWAY TO EXTEND INTO SECOND HALF OF 2021.SAYS EXPECTS TO USE APPROXIMATELY $10 MILLION PER QUARTER AFTER COMPLETING RESTRUCTURING.QUARTERLY GRANT REVENUE $1.9 MILLION VERSUS $10.3 MILLION.  Full Article

Newlink Genetics Outlines 2018 Business Priorities
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Newlink Genetics Corp ::NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS.NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS.NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS.NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018.NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018.  Full Article

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

NewLink Genetics reports Q3 loss per share $0.69
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - NewLink Genetics Corp :Q3 loss per share $0.69.NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​.NewLink Genetics Corp - Qtrly ‍total operating revenues $5.5 million versus $15.3 million.Q3 earnings per share view $-0.74, revenue view $3.4 million -- Thomson Reuters I/B/E/S.  Full Article

Newlink genetics announces FDA orphan-drug designation for Indoximod
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.  Full Article

NewLink Genetics Q3 loss $0.54/shr
Tuesday, 1 Nov 2016 

Newlink Genetics Corp : NewLink Genetics Corp says expects to have approximately $132 million in cash and equivalents on December 31, 2016 . NewLink Genetics Corp - qtrly loss per share $0.54 . Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S .Press release - NewLink Genetics Corp provides operational update and reports third quarter 2016 financial results.  Full Article

Photo

Why the world needs more than one Ebola vaccine

LONDON - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck - seems bound to win.